Pharmaceuticalization of society in context: Theoretical, empirical and health dimensions

Sociology

Volumn 44, Issue 4, 2010, Pages 603-622

  Abraham, John ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

biomedicalism; consumerism; drug innovation; marketing; medicalization; pharmaceutical industry; regulatory state

Indexed keywords

EID: 77955412274     PISSN: 00380385     EISSN: None     Source Type: Journal    
DOI: 10.1177/0038038510369368     Document Type: Article

References (120)

1. Abraham, J. (1994a) Bias in Science and Medical Knowledge; the Opren Controversy, Sociology 28: 717-36.
2. Abraham, J. (1994b) Distributing the Benefit of the Doubt; Science, Regulators and Drug Safety, Science, Technology & Human Values 19: 493-522.
3. Abraham, J. (1995a) Science, Politics and the Pharmaceutical Industry. London/New York: Routledge/ St Martins Press.
4. Abraham, J. (1995b) The Production and Reception of Scientific Papers in the Medical-Industrial Complex, British Journal of Sociology 46: 167-90.
5. Abraham, J. (2002a) Do We Need a Political Sociology of Medicine?, British Sociological Association Conference, York, 8 September.
6. Abraham, J. (2002b) Transnational Industrial Power, the Medical Profession and the Regulatory State, Social Science & Medicine 55: 1671-90.
7. Abraham, J. (2008) Sociology of Pharmaceuticals Development and Regulation: A Realist Empirical Research Programme, Sociology of Health & Illness 30: 869-85.
8. Abraham, J. (2009) 'Partial Progress: Governing the Pharmaceutical Industry and the NHS, 1948-2008', Journal of Health, Politics, Law and Policy 34: 931-77.
9. Abraham, J. and C. Davis (2007a) Deficits, Expectations and Paradigms in British and American Drug Safety Assessments, Science, Technology & Human Values 32: 399-431.
10. Abraham, J. and C. Davis (2007b) Interpellative Sociology of Pharmaceuticals: Problems and Challenges for Innovation and Regulation in the 21st Century, Technology Analysis & Strategic Management 19: 387-402.
11. Abraham, J. and C. Davis (2009) Drug Evaluation and the Permissive Principle, Social Studies of Science 39: 569-98.
12. Abraham, J. and G. Lewis (2000) Regulating Medicines in Europe: Competition, Expertise and Public Health. London: Routledge.
13. Abraham, J. and G. Lewis (2002) Citizenship, Medical Expertise and the Capitalist Regulatory State in Europe, Sociology 36: 67-88.
14. Abraham, J. and T. Reed (2002) Progress, Innovation and Regulatory Science in Drug Development: The Politics of International Standard-setting, Social Studies of Science 32: 337-69.
15. Abraham, J. and J. Sheppard (1998) International Comparative Analysis and Explanation in Medical Sociology: Demystifying the Halcion Anomaly, Sociology 32: 141-62.
16. Abraham, J. and J. Sheppard (1999) The Therapeutic Nightmare: The Battle over the World's most Controversial Sleeping Pill. London: Earthscan.
17. Angell, M. (2004) The Truth about Drug Companies. New York: Random House.
18. Applbaum, K. (2006) Pharmaceutical Marketing and the Invention of the Medical Consumer, PLoS Medicine 3: 445-47.
19. Barkley, R. (1996) Attention-Deficit/Hyperactivity Disorder, in R. Barkley and E. Mash (eds) Child Psychopathology. New York: Guilford Press.
20. Barkley, R. (1997) Behavioural Inhibition, Sustained Attention, and Executive Functions, Psychological Bulletin 121: 65-94.
21. BBC News 24 (2006a) Woman Wins Herceptin Court Fight, http://www.news.bbc.co.uk, 12 April.
22. BBC News 24 (2006b) Herceptin: Was Patient Power Key?, http://www.news.bbc.co.uk, 9 June.
23. BBC News 24 (2007) Alzheimer's Drugs Remain Limited, http://www.news.bbc.co.uk, 10 August.
24. Bird, H., T.J. Yager, B. Staghezza and M.S. Gould (1990) Impairment in the Epidemiological Measurement of Childhood Psychopathology in the Community, Journal of the American Academy of Childhood and Adolescent Psychiatry 29: 796-803.
25. Blumberg, H.M., D.J. Carroll and I.K. Wachsmuth (1991) Rapid Development of Ciprofloxacin Resistance in Methicillin-Susceptible and -Resistant Staphylococcus Aureus, Journal of Infectious Diseases 163: 1279-85.
26. Bradley, J.S., R. Guidos, S. Baragona and J.G. Bartlett (2007) Anti-Infective Research and Development - Problems, Challenges, and Solutions, Lancet Infectious Diseases 7: 68-69.
27. Braithwaite, J. (1984) Corporate Crime in the Pharmaceutical Industry. London: Routledge.
28. Britten, N. (2008) Medicines and Society. Basingstoke: Palgrave.
29. Brown, P. (2006) What Future for Blockbusters?, Scrip Magazine (May): 4-6.
30. Busfield, J. (2006) Pills, Power, People, Sociology 40(2): 297-314.
31. Carpenter, D.P. (2004) The Political Economy of FDA Drug Review, Health Affairs 23: 52-63.
32. Castellanos, X. (2002) Development Trajectories of Brain Volume Abnormalities in Children and Adults with ADHD, Journal of the American Medical Association 288: 1740-48.
33. Centre for Medicines Research (2005) Innovation on the Wane?, Latest News, URL: http://www.cmr.org.
34. Clarke, A.E., J.K. Shim, L. Mamo, J.R. Fosket and J.R. Fishman (2003) 'Biomedicalization: Technoscientific Transformations of Health, Illness, and US Biomedicine', American Sociological Review 68: 161-94.
35. Code of Federal Regulations (1992) Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses, CFR Part 314, Subpart H.
36. Conrad, P. (1992) Medicalisation and Social Control, Annual Review of Sociology 18: 209-32.
37. Conrad, P. (2005a) The Medicalisation of Society. Baltimore, MD: Johns Hopkins University Press.
38. Conrad, P. (2005b) The Shifting Engines of Medicalization, Journal of Health and Social Behaviour 46: 3-14.
39. Conrad, P. and V. Leiter (2008) From Lydia Pinkham to Queen Levitra: Direct-to-Consumer Advertising and Medicalisation, Sociology of Health & Illness 30: 825-38.
40. Conrad, P. and J.W. Schneider (1992) Deviance and Medicalization. Philadelphia, PA: Temple Press.
41. Couvoisie, H. and S.R. Hooper (2003) Neurometabolic Functioning and Neuro-Psychological Correlates in Children with ADHD, Journal of Neuro-Psychiatry and Clinical Neuro-Sciences 16: 63-69.
42. Crinson, I. (2004) The Politics of Regulation within the Modernised NHS, Critical Social Policy 24: 30-49.
43. Daemmrich, A. and G. Krucken (2000) Risk versus Risk, Science as Culture 9: 505-34.
44. DeGrandpre, R. (2000) Ritalin Nation. New York: W.W. Norton.
45. Department of Health (1994) Prescription Cost Analysis. London: Government Statistical Service.
46. Department of Health (2001) The Expert Patient. London: HMSO.
47. Department of Health (2003) Prescription Cost Analysis. London: Government Statistical Service.
48. Diller, L. (1998) Running on Ritalin. New York: Bantam Books.
49. Drug Enforcement Administration (2001) Aggregate Production Quota History, 1992-2002. Washington, DC: Department of Justice.
50. Edgar, H. and D.J. Rothman (1990) New Rules for New Drugs, The Milbank Quarterly 68: 111-42.
51. Eli Lilly (2000) Eli Lilly Annual Report 2000.
52. Epstein, S. (1996) Impure Science. Berkeley, CA: University of California Press.
53. FDA (2004) Review and Approval Times for Priority and Standards NMEs, URL: http://www.fda.gov.
54. FDA (2009) CDER Approval Times for Priority and Standard NMEs 1993-2008, URL: http://www.fda.gov/cder/rdmt/default.htm.
55. Fleming, T.R. (2005) Surrogate Endpoints and FDA's Accelerated Approval Process, Health Affairs 24: 67-78.
56. Fox, N.J. and K.J. Ward (2009) Pharma in the Bedroom... and the Kitchen... The Pharmaceuticalisation of Daily Life, in S.J. Williams, J. Gabe and P. Davis (eds) Pharmaceuticals and Society, pp. 41-53. Chichester: Wiley-Blackwell.
57. Fraser, S., K. Valentine and C. Roberts (2009) Living Drugs, Science as Culture 18: 123-31.
58. Freidson, E. (1970) Profession of Medicine. London: University of Chicago Press.
59. Gabe, J. and M. Bury (1988) Tranquillisers as a Social Problem, Sociological Review 36: 320-52.
60. Gale, E.A.M. (2001) Lessons from the Glitazones, Lancet 357: 1871.
61. Glenmullen, J. (2000) Prozac Backlash. New York: Simon & Schuster.
62. Goldman, L.S., M. Genel and R.J. Bezman (1998) Diagnosis and treatment of ADHD in Children and Adolescents, Journal of the American Medical Association 279: 1100-7.
63. Harding, R. (2001) Unlocking the Brain's Secrets, Family Circle (20 November): 10-11.
64. HCHC (2005) Inquiry into the Influence of the Pharmaceutical Industry: Health Select Committee Report. London: TSO.
65. Healy, D. (2004) Let Them Eat Prozac. London: New York University Press.
66. Healy, D. (2006a) The Latest Mania: Selling Bipolar Disorder, PLoS Medicine 3: 441-4.
67. Healy, D. (2006b) The New Medical Oikumene, in A. Petryna, A. Lakoff and A. Kleinman (eds) Global Pharmaceuticals, pp. 61-84. London: Duke University Press.
68. Herxheimer, A. (2003) Relationships between the Pharmaceutical Industry and Patients' Organizations, British Medical Journal 326: 1208-10.
69. IMS Health (2008) Global Pharmaceutical Sales 2000-2007, URL: http://www.imshealth.com/deployedfiles/imshealth/global/content/statcfile.pdf.
70. Infectious Diseases Society of America (2004) Bad Bugs, No Drugs. Alexandria, VA: ISDA.
71. Jones, K. (2008) In Whose Interest? Relationships between Health Consumer Groups and the Pharmaceutical Industry in the UK, Sociology of Health & Illness 30: 929-43.
72. Kaitin, K.I. and J. Di Masi (2000) Measuring the Pace of New Drug Development in the User Fee Era, Drug Information Journal 24: 673-680.
73. Kessler, D.A., A.E. Hass, K.L. Feiden, M. Lumpkin and R. Temple (1996) Approval of New Drugs in the US, Journal of the American Medical Association 276: 1826-31.
74. Kirsch, I., B.J. Deacon, T.B. Huedo-Medina, A. Scoboria, T.J. Moore and B.T. Johnson (2008) Initial Severity and Antidepressant Benefits, PloS Medicine 5: 260-68.
75. Krause, K., S.H. Dresel, J. Krause and C. la Fougere (2003) The Dopamine Transporter and Neuro-imaging in ADHD, Neuro-Science Bio-Behavioural Review 27: 605-13.
76. La Revue Prescrire (2005) A Review of New Drugs in 2004, Prescrire International 14: 68-73.
77. Lexchin, J. (2001) Lifestyle Drugs, Canadian Medical Association Journal 164: 1449-51.
78. Lexchin, J., L.A. Bero, B. Djulbegovic and O. Clark (2003) Pharmaceutical Industry Sponsorship and Research Outcomes and Quality, British Medical Journal 326: 1167-70.
79. Lofgren, H. (2004) Pharmaceuticals and the Consumer Movement, Australian Health Review 28: 228-37.
80. Marshall, B.L. (2009) Sexual Medicine, Sexual Bodies and Pharmaceutical Imagination, Science as Culture 18: 133-49.
81. Martin, E. (2006) The Pharmaceutical Person, BioSocieties 1: 273-87.
82. Medawar, C. (1992) Power and Dependence. London: Social Audit.
83. Medawar, C. and A. Hardon (2004) Medicines out of Control? Amsterdam: Askant.
84. Milewa, T. (2009) 'Health Care, Consumerism and the Politics of Identity', in J. Gabe and M. Calnan (eds) The New Sociology of the Health Service, pp. 161-76. London: Routledge.
85. Mintzes, B., M.L. Barer, R.L. Kravitzet al.(2003) How does Direct-to-Consumer Advertising Affect Prescribing?, Canadian Medical Association Journal 169: 405-12.
86. Moynihan, R. and A. Cassels (2005) Selling Sickness. Crows Nest, Australia: Allen & Unwin.
87. O'Donovan, O. (2007) Corporate Colonisation of Health Activism?, International Journal of Health Services 37: 711-33.
88. O'Neill, P. and S. McIntosh (1987) Bacteria Resistant to Antibiotics Spread Concern, New Scientist (27 August): 16.
89. Parsons, T. (1951) The Social System. New York: Free Press.
90. Padwal, R.S. and S.R. Majumdar (2007) Drug Treatments for Obesity, Lancet 369: 71-7.
91. Phillips, C.B. (2006) Medicine Goes to School, PLoS Medicine 3: 433-35.
92. Rafalovich, A. (2005) Exploring Clinician Uncertainty in the Diagnosis and Treatment of ADHD, Sociology of Health & Illness 27: 305-23.
93. Roberts, T.G. and B.A. Chabner (2004) Beyond Fast Track for Drug Approvals, New England Journal of Medicine 351: 501-3.
94. Rose, N. (2007) Beyond Medicalisation, Lancet 369: 700-2.
95. Schweitzer, S.O., M.E. Schweitzer and M-J. Sourty-LeGuellec (1996) Is there a US Drug Lag?, Medical Care Research and Review 53: 162-78.
96. Scrip (1988) Bush Calls for Speedier US Approvals, Scrip Magazine 1335: 16.
97. Scrip (1995) SSRIs - Unprecedented US Growth, Scrip Magazine 2020: 23.
98. Scrip (1999) Pfizer's Pharma Sales Soar 28%, Scrip Magazine 2405: 8.
99. Scrip (2006) A Slap on the Wrist for Pharma over Promotion Tactics, Scrip Magazine (April): 10.
100. Scrip (2007) Merck & Co Settles Vioxx Claims for US$4.85 Billion, Scrip Magazine 3311: 12-13.
101. Scrip (2008a) 14 Drugs Widely Used Off Label Need More Review, US Study Says, Scrip Magazine (28 November): 34.
102. Scrip (2008b) Australia and NZ See Retail Growth while Europe Shows Modest Sales, Scrip Magazine (6 February): 36.
103. Scrip (2008c) US Prescription Drug Sales Growth, Scrip 3346: 16.
104. Scrip (2008d) Pfizer to Settle Celebrex and Bextra Suits for US$894m, Scrip Magazine 3407: 1-4.
105. Scrip (2008e) Pharma Industry Abusing its Position of Trust, Scrip Magazine 3343: 2.
106. Scrip (2009) Largest ever Fine for Lilly in US over Zyprexa, Scrip Magazine 3429: 5-7.
107. Sharma, V. (2000) Diagnostic Co-morbidity, Attentional Measures, and Neuro-chemistry in Children with ADHD, in L. Greenhill and B. Osman (eds) Ritalin: Theory and Practice. Larchmont, MD: Liebert.
108. Spellberg, B., J.H. Powers, E.P. Brass, L.G. Miller and J.E. Edwards (2004) Trends in Antimicrobial Drug Development, Clinical Infectious Diseases 38: 1279-86.
109. Stevenson, F.A., M. Leontowitsch and C. Guggan (2009) Over-the-Counter-Medicines: Professional Expertise and Consumer Discourses, in S. Williams, J. Gabe and P. Davis (eds) Pharmaceuticals and Society, pp. 97-111. Chichester: Wiley-Blackwell.
110. Thambirajah, M. (1998) Attention Deficit Hyperactivity Disorder in Children, British Medical Journal 317: 1250.
111. Throsby, K. (2009) The War on Obesity as a Moral Project, Science as Culture 18: 201-16.
112. Timmerman, L. (2003) Impotence Drug Cialis gets OK for Sales in US, The Seattle Times, 22 November.
113. Van Klingeren, B., M. Dessens-Kroon and M. Verheuvel (1989) Increased Tetracycline Resistance in Gonococci in the Netherlands, Lancet (25 November): 1278.
114. Vos, R. (1991) Drugs Looking for Diseases. Dordrecht: Kluwer.
115. WHO (2004) Priority Medicines for Europe and the World. Geneva: WHO.
116. Williams, S.J., J. Gabe and P. Davis (2009a) The Sociology of Pharmaceuticals, in S. Williams, J. Gabe and P. Davis (eds) Pharmaceuticals and Society, pp. 1-11. Chichester: Wiley-Blackwell.
117. Williams, S.J., C. Seale, S. Boden, P. Lowe and D. Lynn (2009b) Waking up to Sleepiness, in S. Williams, J. Gabe and P. Davis (eds) Pharmaceuticals and Society, pp. 25-40. Chichester: Wiley-Blackwell.
118. Yuwiler, A. (1994) The Basics of Serotonin Neuro-chemistry, in R. Maters and M. McGuire (eds) The Neuro-transmitter Revolution. Carbondale, IL: Southern Illinois University Press.
119. Zametkin, A.J., T.E. Nordhal, M. Gross, A.C. King, W.E. Semple, J. Rumsey, S. Hamburger and R.M. Cohen (1990) Cerebral Glucose Metabolism in Adults with Hyperactivity of Childhood Onset, New England Journal of Medicine 3231: 361-66.
120. Zola, I.K. (1972) Medicine as an Institution of Social Control, Sociological Review 20: 487-503.